Solara Active Pharma Sciences has revised the effective joining date of Mr. Ajit Manocha as Chief Information Officer (CIO) and Senior Management Personnel (SMP). The change pushes his start date from August 10, 2026, to August 17, 2026, following a request from Mr. Manocha on account of personal reasons. This update supersedes the company’s earlier intimation dated July 23, 2026, regarding his appointment.

The disclosure was made to the stock exchanges on August 07, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing also references SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Pooja Jaya Kumar, Company Secretary & Compliance Officer, signed the communication.

Appointment Details

Mr. Manocha’s appointment remains confirmed for the role of CIO within the Senior Management Personnel framework. The delay does not alter the nature of the role or the strategic intent behind the hiring, but simply adjusts the timeline for his onboarding.

Profile Overview

Mr. Ajit Manocha brings over 33 years of experience in global technology and Life Sciences transformation. His expertise spans digital transformation across pharmaceuticals, CRDMOs, manufacturing, and other regulated industries. He specializes in aligning technology strategy with business goals, leading enterprise-wide SAP and S/4HANA transformations, and implementing Industry 4.0, IoT, cybersecurity, and AI/ML/Generative AI initiatives.

His background includes extensive work with Boards and senior leadership on technology strategy, cyber risk, and governance, ensuring the protection of intellectual property and data integrity in highly regulated environments. There are no disclosed relationships between Mr. Manocha and the company’s directors.

Solara Active Pharma Sciences Limited reported a 20% year-on-year rise in revenue to ₹384 crore for Q1 FY27, driven by strong performance in its base business despite headwinds from the West Asia crisis. The company achieved its highest EBITDA of ₹63.5 crore and net profit (PAT) of ₹16.3 crore in 18 quarters, with PAT surging 55% year-on-year. Management highlighted disciplined execution and working capital optimization as key drivers, while noting that the ibuprofen segment continues to face profitability challenges.

The earnings conference call, held on July 23, 2026, was conducted pursuant to Regulation 30 and Regulation 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The transcript was uploaded to the company’s website and stock exchanges on July 29, 2026, by Pooja Jaya Kumar, Company Secretary and Compliance Officer (ICSI Membership No. A57415).

Financial Performance

Solara’s base business revenue reached ₹307 crore, up 24% year-on-year, contributing significantly to the overall growth. Gross margins for the base business stood at ₹158 crore, up 10% year-on-year, with an EBITDA of ₹72 crore, up 8% year-on-year. The consolidated EBITDA margin improved by 80 basis points quarter-on-quarter to 17%.

Balance Sheet and Debt Reduction

The company reduced its net debt by approximately ₹135 crore during the quarter, representing a 22% reduction. This deleveraging was supported by ₹100 crore from the final call money of the rights issue realized in May 2026 and ₹35 crore from operational cash flows. As of June 30, 2026, net debt stood at ₹479 crore, implying a net debt-to-EBITDA multiple of roughly 1.9x based on annualized Q1 EBITDA. Management indicated a line of sight to reduce debt to sub-₹450 crore, approximately ₹440 crore, by March 2027, which would improve the multiple to roughly 1.7x.

Operational Challenges and Strategic Review

The ibuprofen business continues to face profitability challenges, reporting an EBITDA margin of negative 12%. Management attributed this to a difficult operating environment driven by solvent shortages and geopolitical tensions in West Asia, which impacted raw material availability and pricing. Despite this, there was a marginal sequential improvement in the quarter. The company expects the ibuprofen segment to incur an EBITDA loss between ₹10 crore and ₹15 crore per quarter in the near term.

A strategic review of the ibuprofen business is ongoing, with management confirming it is on track to conclude by H1 FY27. No final decision has been made regarding the future of the unit, though management noted that recovering the entire deployed capital of approximately ₹700 crore may be challenging.

What the Numbers Show

The divergence between the robust growth in the base business and the persistent losses in the ibuprofen segment highlights Solara’s shifting focus toward higher-margin API products. While raw material cost pressures from the West Asia crisis have introduced volatility in gross margins, the company’s ability to pass through costs—accounting for roughly ₹30 crore of consolidated revenue growth—has protected absolute margin values. The aggressive debt reduction strategy, fueled by rights issue proceeds and operational cash flows, positions the company to become net-debt-free by FY29, assuming continued execution on debottlenecking capex projects aimed at enhancing capacity utilization across its Cuddalore, Bangalore, and Ambernath sites.